News for GRAY Stock

Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors Graybug Announces Name and Trading Symbol Change Graybug and CalciMedica Enter into Definitive Merger Agreement Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022 Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments Graybug to Present at the 2022 OIS Retina Innovation Summit Graybug Announces Review of Strategic Alternatives Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting Graybug to Present at the 2022 ASCRS Annual Meeting Graybug Vision Appoints Dirk Sauer to Board of Directors Graybug Announces Pipeline Expansion, Current Cash Expected to Deliver Three Clinical Readouts in 2023 Graybug Vision to Host Virtual R&D Day on March 30, 2022 Graybug Vision Reports Full Year 2021 Financial Results and Recent Corporate Developments Graybug to Participate in Three Upcoming Medical and Investor Conferences Graybug Vision Makes Key Hires to Further Build Momentum Behind its Pipeline Graybug Vision to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2021, and Recent Corporate Developments Graybug Vision to Participate in the American Academy of Ophthalmology 2021 Annual Meeting Graybug Vision to Participate in the Annual Ophthalmology Innovation Summit (OIS) Retina@ASRS Conference Graybug Vision Reports Analysis of Data from the Six-Month Extension Study of the ALTISSIMO Phase 2b Trial in Wet AMD Graybug Vision to Participate in the Cantor Virtual Global Healthcare Conference Graybug Vision Announces Financial Results for the Three and Six Months Ended June 30, 2021, and Recent Corporate Developments Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference Graybug Vision Announces First Quarter 2021 Financial Results and Recent Corporate Developments Graybug Vision Reports Full-Data Analysis from 12-Month Treatment Phase of ALTISSIMO Phase 2b Trial in Wet AMD Graybug Vision to Report Full-Data Analysis of the 12-month Treatment Phase of its Phase 2b ALTISSIMO Trial Graybug Vision Reports Preliminary Topline Results from Phase 2b ALTISSIMO Trial Graybug Vision Announces Full Year 2020 Financial Results and Recent Corporate Developments Graybug Vision to Participate in SVB Leerink Global Healthcare Conference Graybug Vision Appoints Bettina Maunz as Chief People Officer, Expanding the Company’s Executive Team Graybug Vision Completes Treatment Phase of ALTISSIMO Trial in Wet AMD with 12-Month Topline Data Expected in Second Quarter 2021 Graybug Vision to Participate in the 32nd Annual Piper Sandler Healthcare Conference Graybug Vision Announces Financial Results for the Three and Nine Months Ended September 30, 2020 and Recent Corporate Developments Graybug Appoints Three New Members to its Board of Directors Graybug Vision Announces Pricing of Upsized Initial Public Offering